Share This Page
Drugs in ATC Class D05AX
✉ Email this page to a colleague
Drugs in ATC Class: D05AX - Other antipsoriatics for topical use
| Tradename | Generic Name |
|---|---|
| CALCITRIOL | calcitriol |
| ROCALTROL | calcitriol |
| CALCIJEX | calcitriol |
| VECTICAL | calcitriol |
| >Tradename | >Generic Name |
Market Dynamics and Patent Landscape for ATC Class D05AX – Other Antipsoriatics for Topical Use
What Are the Key Market Drivers?
The topical antipsoriatic segment under ATC Class D05AX has experienced moderate growth driven by several factors:
- Rising Psoriasis Prevalence: An estimated 2-3% of the global population suffers from psoriasis. The increase in diagnosed cases, particularly in developed regions, fuels demand for topical therapies.
- Advances in Topical Formulations: Innovations integrating enhanced absorption, reduced side effects, and improved patient compliance contribute to market expansion.
- Limited Systemic Side Effects: Topical antipsoriatics are preferred over systemic agents due to a lower risk profile, encouraging their use across different severity levels.
Which Companies Lead the Market?
Major players include:
- Leo Pharma: Known for Calcipotriol, a vitamin D analog used up to 50 weeks/year.
- AbbVie: Offers topical corticosteroids such as clobetasol propionate.
- Galderma: Developed formulations combining calcipotriol and corticosteroids.
Emerging companies focus on niche formulations, including non-steroidal options, aiming to distinguish in patent-protected markets.
Market Trends and Opportunities
- Biologic Alternatives: While oral and injectable biologics target moderate to severe cases, their high cost promotes continued reliance on topical agents for mild cases.
- Combination Products: Fixed-dose combinations of corticosteroids with vitamin D analogs lead in efficacy and adherence.
- Patient-Centric Formulations: Development of improved vehicles, such as foams and gels, enhances ease of application and absorption.
- Regional Variations: High-growth markets include Asia-Pacific and Latin America, driven by increasing awareness and healthcare infrastructure expansion.
Patent Landscape Overview
Patent activity, particularly from pharmaceutical companies, has centered around:
| Patent Type | Focus Areas | Key Innovations | Timeline |
|---|---|---|---|
| Composition Patents | Vitamin D analogs, corticosteroid combinations | Extended formulations, reduced side effects | 2010–2022 |
| Delivery Method Patents | Foam, gel, and patch delivery systems | Enhanced absorption, reduced application frequency | 2012–2023 |
| Use Patents | Specific indications, combination use, novel dosing | Improved efficacy with fewer application steps | 2014–2022 |
Companies such as Leo Pharma and Galderma have secured key patents covering topical formulations and their use for psoriasis, with patent lifespans extending into the late 2030s.
Patent expirations and Opportunities
- Several composition patents expire between 2025 and 2030, opening prospects for generic development.
- Formulation patents, particularly for novel delivery systems, tend to have longer protection, often until 2035.
- Patent cliffs may lead to increased licensing activity and competition.
Regulatory and R&D Impact
Regulatory pathways primarily involve topical drug applications approved by agencies like the FDA and EMA. Companies are investing in:
- Demonstrating bioequivalence for generic entries.
- Developing next-generation formulations with improved safety profiles.
- Expanding indications to include combination therapies for resistant psoriasis.
Key Takeaways
- The ATC D05AX segment benefits from rising psoriasis prevalence and formulation innovation.
- Market leaders leverage patent protections around formulations and delivery systems.
- Patent expirations will likely stimulate market entry of generics and biosimilars.
- Players focusing on patient compliance and regional market expansion hold growth potential.
- The patent landscape reveals a strategic focus on combination products and advanced delivery systems.
FAQs
1. What are the dominant patents in D05AX covering topical psoriasis agents?
Patents mainly cover vitamin D analogs, corticosteroid combinations, and delivery systems like foams and gels. Composition and use patents dominate, with some focusing on specific formulations for improved absorption or reduced side effects.
2. When do key patents for current topicals expire?
Most composition patents expire between 2025 and 2030, while delivery system patents may extend until 2035, creating windows for generic entry.
3. Are there new innovation trends in topical antipsoriatics?
Yes. Focus areas include non-steroidal formulations, combination therapies for resistant cases, and delivery systems that improve patient adherence.
4. How does regional patent activity differ?
Developed markets prioritize formulation innovations and use patents, whereas emerging markets emphasize access and local manufacturing. Patent filings are globally distributed, with significant activity in the US, Europe, and Asia-Pacific.
5. What regulatory factors influence the market?
Regulators require demonstrating safety, efficacy, and bioequivalence. Patent protections can influence approval timelines and market exclusivity durations, especially for biosimilars.
References
- World Health Organization. (2021). Psoriasis. Retrieved from https://www.who.int
- Grand View Research. (2022). Topical Psoriasis Market Size, Share & Trends Analysis.
- U.S. Patent and Trademark Office. (2022). Patent Data for Topical Psoriasis Agents.
- European Patent Office. (2022). Patent Applications on Skin Treatment Formulations.
- Food and Drug Administration. (2022). Approval Processes for Topical Dermatological Products.
More… ↓
